Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Emergent BioSolutions excels in Q3, poised for growth opportunities

Emergent BioSolutions delivered a strong Q3 performance, showcasing financial resilience, operational excellence, and strategic advancements across key business segments.
While facing challenges in pricing dynamics and revenue mix, the company's focus on growth opportunities, compliance, and leadership appointments positions them for sustained success.
With a solid financial foundation, improved guidance, and a strategic roadmap for growth, Emergent is well-equipped to navigate challenges, capitalize on opportunities, and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Company continues to be on track with its manufacturing agreements related to COVID-19 vaccines and confirmed that there are no changes to its financial guidance for 2021. In addition, the Company received a contract modification to increase the original task order by $23 million from Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services (HHS).

Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & John

AstraZeneca

Johnson & Johnson

Johnson & Johnson has been put in charge of COVID-19 vaccine production at a Baltimore plant where 15 million doses were ruined several weeks ago. What Happened: The U.S. Department of Health and Human Services put Johnson & Johnson (NYSE: JNJ) in charge of the Emergent BioSolutions Inc (NYSE: EBS) plant in Baltimore.

US Puts Johnson & Johnson In Charge Of Troubled Vaccine Plant In Baltimore, Removes AstraZeneca

Emergent BioSolutions Inc. said Friday that its experimental COVID-19 treatment did not demonstrate a clinical benefit in a late-stage clinical trial. The study was testing Emergent's immunoglobulin candidate with the standard of care, which uses Gilead Sciences Inc.'s Veklury, in hospitalized patients with COVID-19 symptoms.

Emergent says experimental COVID-19 treatment failed in Phase 3 trial

GAITHERSBURG, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) for the treatment of hospitalized patients with COVID-19. The Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) trial, also known as INSIGHT-013, sponsored and supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), assessed the safety and efficacy of four immunoglobulin candidates plus standard of care versus placebo plus standard of care in hospitalized patients with COVID-19. Topline data from the ITAC trial demonstrated that the addition of anti-SARS-CoV-2 hyperimmunoglobulin to standard of care, inclusive of remdesivir, for hospitalized adult COVID-19 patients with symptoms for less than 12 days did not provide clinical benefit when compared to standard of care plus placebo. There were no serious safety concerns identified.

Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19

The company appears to have fumbled part of a very high-profile job for a big partner.

Why Emergent BioSolutions Crashed Today

Shares of Emergent BioSolutions tumbled 7.44% in premarket trading on Thursday after Johnson & Johnson said the biopharmaceutical manufacturing plant spoiled 15 million COVID-19 vaccine doses.  Emergent BioSolutions is a contract manufacturer that produces both the Johnson & Johnson and AstraZeneca coronavirus vaccines.

Emergent BioSolutions tumbles 7% after J&J says it spoiled 15 million COVID-19 vaccine doses (EBS, JNJ, AZN)

Emergent stock falls nearly 7% after news of J&J vaccine manufacturing mix-up

Johnson & Johnson confirmed yesterday that a batch of its Covid-19 vaccine was contaminated by ingredients from AstraZeneca's vaccine at Emergent Biosolutions' manufacturing plant in Baltimore due to a “human error.” While Johnson & Johnson said it will still be on track to deliver the promised.

Emergent Biosolutions Stock Takes A Hit From Vaccine Mix-Up At Baltimore Plant

Chemed

DaVita

ICON

Select Medical Holdings

The following health care companies have grown their earnings per share over a five-year period. According to the GuruFocus discounted cash flow calculator as of March 31, all of them also trade with a margin of safety.

5 Health Care Stocks Boosting Earnings

Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock?

Why Is Emergent Biosolutions (EBS) Down 22.3% Since Last Earnings Report?

The New York Times (NYSE: NYT) is crediting its reporting for President Joe Biden's decision to cancel a visit to a coronavirus vaccine plant operated by Emergent BioSolutions (NYSE: EBS) and launch an investigation into the Strategic National Stockpile, the nation's emergency medical reserve. What Happened: On March 6, the newspaper published the article “How One Firm Put an ‘Extraordinary Burden' on the U.S.'s Troubled Stockpile,” which offered insight into what the Times described as “Emergent's aggressive tactics, broad political connections and penchant for undercutting competitors have given it remarkable sway over the government's purchasing decisions related to the vaccines.

New York Times Credits Report On Emergent BioSolutions For Biden's Canceled Vaccine Plant Visit

Emergent CEO Bob Kramer told CNBC that the company has infrastructure in place to produce Johnson & Johnson and AstraZeneca vaccines around the clock.

Emergent BioSolutions says it can make 1 billion Covid vaccine doses annually

The stock price of Emergent Biosolutions, a biopharmaceutical company focused on vaccines and antibody therapeutics for infectious diseases, and opioid overdoses, has seen a 17% drop over the last ten trading days, while it's down 19% over the last five trading days, and we believe the stock may.

What Should You Do With Emergent Biosolutions Stock After A 19% Drop In 5 Days?

Abercrombie & Fitch

Mattel

Western Digital

Allakos Inc

Evolus

Generation Bio

Schnitzer Steel Industries Inc

Thomson Reuters

With the trading day more than halfway over, the broad markets have pushed higher, seemingly recovering from Tuesday.

Abercrombie, Mattel, Western Digital and More Wednesday Afternoon Analyst Calls

Crocs

Macy's

CNA Financial

Montauk Renewables

Molina Healthcare

Newmark Group

NeoPhotonics

With the trading day more than halfway over, the broad markets were sliding into the weekend.

Crocs, Emergent Bio, Macy's and More Friday Afternoon Analyst Calls

Why Emergent BioSolutions Stock Is Sliding Today

Emergent's (EBS) earnings in the fourth quarter of 2020 beat estimates while revenues miss the same. Sales of contract development and manufacturing services rise.

Emergent (EBS) Beats on Q4 Earnings, Misses on Revenues

Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q4 2020 Results - Earnings Call Transcript

Shares of Emergent BioSolutions (NYSE:EBS) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 133.76% over the past year to $3.67, which beat the estimate of $3.19.

Emergent BioSolutions: Q4 Earnings Insights

GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2020. The Company also reaffirmed its full year 2021 forecast.

Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020

Pfizer

Regeneron Pharmaceuticals

These stocks would be buys even without the pandemic.

3 Absurdly Cheap Coronavirus Stocks to Buy Now

GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments, financial outlook for full year 2021, and revenue guidance for the first quarter of 2021.

Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021

Humanigen

Shares of Humanigen Inc. were down 2.5% in trading on Monday after it announced a contract development and manufacturing deal with Emergent BioSolutions Inc. for its experimental COVID-19 treatment. Emergent's stock was down 1.7%.

Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug

GAITHERSBURG, Md. & BURLINGAME, Calif.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) (Emergent) and Humanigen, Inc. (NASDAQ:HGEN) (Humanigen) today announced that they have entered into a contract development and manufacturing (CDMO) services agreement to accelerate the drug product manufacturing of lenzilumab™, an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune hyper-response called “cytokine storm.” Eme

Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™

Emergent BioSolutions remains well insulated from peers, with key COVID-19 vaccine drivers and exposure to adjacent specialty markets in public crises prevention. Additional drivers in contract manufacturing continue to present for the company, which should contribute to revenue volumes in periods to come.

News for Emergent BioSolutions Stock (EBS)